Check Claims Before You Publish

Author review highlight — name disambiguation required

• Nature 2001 — p27 knock‑in cell-cycle study (DOI 10.1038/35095083)
• PNAS 2003 — caspase‑8 siRNA in acute liver failure (DOI 10.1073/pnas.1330920100)
• Nature 2021 — NASH limits immunotherapy in HCC (DOI 10.1038/s41586-021-03362-0)

Author Review: "Nisar P. Malek" — scientific-strength critique (visual-first)

Detailed evidence and critical points

1. Name ambiguity and why it matters
   Your supplied author metadata (h-index 2, 23 total citations, 11 papers) indicates a relatively early-stage or local-clinical author profile focused on personalized oncology workflows and feasibility studies; OpenAlex returned multiple matches including a high-impact author (h≈56, works_count 389, cited_by_count ≈10201) — those are distinct bibliometric portraits. Evaluate only after ORCID/affiliation disambiguation to avoid false inferences about competence or influence.
2. High-impact publications associated with the name
   Examples below show that an author named N. P. Malek appears on major papers spanning basic cell-cycle biology (Nature 2001), RNAi therapeutics in liver failure (PNAS 2003), and cancer/immunology (Nature 2021). These items are individually high quality by journal, citation count, and likely peer-review standards — but coauthorship position and contribution levels vary across papers; do not assume PI-level contribution without checking author position, contributions, and acknowledgements.
3. Citation metrics are necessary but insufficient
   High h-index or citation totals indicate influence but not necessarily independent leadership, reproducibility, or current active contribution. Conversely, low citation counts for the 11-paper record could reflect a clinical/implementation focus (app-based feasibility, tumor board workflows) that is inherently less-cited but still clinically useful. Always inspect methods, sample sizes, effect sizes, and reproducibility indicators per paper.
4. Typical blindspots to guard against
   - Name ambiguity (author disambiguation) — primary risk here.
   - Conflating coauthorship presence with intellectual leadership.
   - Over-reliance on journal-level prestige instead of study design quality (sample size, controls, blinding, statistical rigor).
   - Publication and citation biases (large consortia often attract citations independent of any single author's contribution).

Representative citations (to verify presence of this name in major papers)

• Nature 2001 — p27 knock-in model (DOI 10.1038/35095083) — shows the name on a high-impact cell-cycle paper.
• PNAS 2003 — Caspase 8 siRNA (DOI 10.1073/pnas.1330920100) — translational RNAi study listing the name.
• Nature 2021 — NASH limits anti‑tumour surveillance (DOI 10.1038/s41586-021-03362-0) — modern, high-profile cancer/immunotherapy contribution.
• Nature Metabolism 2022 — NASH mouse model review (DOI 10.1038/s42255-022-00700-y) — review coauthorship that indicates ongoing relevance in liver disease research.

Practical recommendations for an evidence-based evaluation

1. Disambiguate identity: obtain ORCID or institutional affiliation, then re-run bibliometric queries (Scopus/Web of Science/OpenAlex) limited to that ORCID to avoid conflation.
2. Assess per-paper contribution: check author position, contributions statement, funding statements, and role (corresponding/first/last).
3. Read a representative sample of methods/results from both the 11-paper clinical set and the high-impact basic-science papers to compare study designs (sample sizes, controls, endpoints).
4. Evaluate reproducibility signals: presence of raw data, code availability, independent replication, pre-registration (if clinical), and consistency across cohorts.

Conclusions (visual, concise)

• Name ambiguity dominates: do not judge scientific strength until you specify which "Nisar P. Malek" (ORCID/affiliation) you mean.
• If you mean the low-citation 11-paper record: likely early-stage clinical/implementation researcher with focused outputs on personalized oncology workflows (feasibility and harmonization studies) — useful clinically but limited citation impact so far.
• If you mean the high-impact OpenAlex author: the name appears on multiple high-quality, highly-cited basic and translational research papers (Nature/PNAS/Nature Medicine), indicating substantial prior scientific impact — but you must verify if the same person authored both sets.